Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
IHC - Paraffin (5 - 10 µg/ml), Western blot (1:2000 - 1:10000), Immunoprecipitation (2 - 5 µg/tst)
Specificity and Use
PPP1R13L / iASPP antibody was raised against the epitope recognized by this antibody maps to a region between residue 75 and 125 of human inhibitor of apoptosis stimulating protein of p53 using the numbering given in entry NP_006654.2.
Recognizes human RBM25.
Suitable for use in Western Blot and Immunoprecipitation. Western Blot: 1:2000-1:10000,. immunoprecipitation: 2-5 ug/mg lysate.
TBS, 0.1% BSA, 0.09% sodium azide
Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.
PPP1R13L Antibody, IASPP Antibody, Inhibitor of ASPP protein Antibody, NFkB-interacting protein 1 Antibody, NKIP1 Antibody, RAI4 Antibody, RAI Antibody, Retinoic acid induced 4 Antibody, NFkB interacting protein 1 Antibody, PPP1R13BL Antibody, Protein iASPP Antibody, RelA-associated inhibitor Antibody, PPP1R13B-like protein Antibody
Regulator that plays a central role in regulation of apoptosis and transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis.